Monday, November 9, 2026

EUR/CHF Bullish By 1% In The Last 10 Sessions

ViaNews Editorial Team

November 11, 2023

EUR/CHF Bullish By 1% In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.09% for the last 10 sessions. At 19:06 EST on Friday, 10 November, EUR/CHF (EURCHF) is $0.96.

EUR/CHF's yearly highs and lows, it's 2.315% up from its 52-week low and 4.576% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was 0.07%, 0.01%, and 0.25%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.16% (last week), 0.30% (last month), and 0.25% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy price analysis: sticks to modest gains around mid-150.00s, looks to fed’s powell. According to FXStreet on Wednesday, 8 November, "The Japanese Yen (JPY) continues with its relative underperformance in the wake of a more dovish stance adopted by the Bank of Japan (BoJ), which, in turn, is seen acting as a tailwind for the USD/JPY pair. ", "The said handle might also act as a key pivotal point for short-term traders, which if broken decisively could drag the USD/JPY pair back towards the 200-period SMA on the 4-hour chart, currently pegged near the 149.55 area. "
  • Usd/jpy hung up near 150.50 after greenback gains for a second day. According to FXStreet on Wednesday, 8 November, "The USD/JPY is trading into the 150.50 neighborhood after the pair eked out a second straight day of gains following last week's three-day decline into 149.20.", "The USD/JPY continues to grind higher on the daily candlesticks, and the pair is catching some technical lift in a bounce off of a rising trendline from July's swing lows into the 138.00 handle."
  • The turn lower in usd/jpy and eur/jpy is closer now – socgen. According to FXStreet on Thursday, 9 November, "The Yen will doubtless frustrate for a while longer, but the turn lower in USD/JPY and EUR/JPY is closer now. "
  • Usd/jpy seen peaking at 154 heading into a December fed hike – CIBC. According to FXStreet on Wednesday, 8 November, "After the latest tweak to YCC, USD/JPY is likely to shadow moves in long-end UST over the coming months, economists at CIBC Capital Markets report.", "Japan's authorities could intervene to slow Yen weakness at 152 (they were very vocal about one-sided moves after the October BoJ decision), but our view for higher US yields points to USD/JPY peaking at 154 heading into a December Fed hike."
  • Usd/jpy: highs are challenging apex levels as jitters grow - 08 November 2023. According to DailyForex on Wednesday, 8 November, "Traders need to grasp the upwards climb the USD/JPY has sustained since the middle of January 2023 when the currency pair was near the 127.600 mark. ", "S Federal Reserve's FOMC Statement in which the interest rate remained the same the USD/JPY began to move lower again, and by Thursday the pair was near 149.860. "

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com